Shareholders' equity · 2015–2025
AstraZeneca shareholders' equity
$48.7B+19.3% · FY2025
AstraZeneca (AZN) reported $48.7B in shareholders' equity for fiscal 2025, +19.3% year on year.
| Fiscal year | Shareholders' equity | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $48.7B | +19.3% | Open → |
| FY20242024-12-31 | $40.8B | +4.2% | Open → |
| FY20232023-12-31 | $39.1B | +5.7% | Open → |
| FY20222022-12-31 | $37.0B | −5.7% | Open → |
| FY20212021-12-31 | $39.3B | +151.4% | Open → |
| FY20202020-12-31 | $15.6B | +19.0% | Open → |
| FY20192019-12-31 | $13.1B | +5.3% | Open → |
| FY20182018-12-31 | $12.5B | −16.7% | Open → |
| FY20172017-12-31 | $15.0B | +0.7% | Open → |
| FY20162016-12-31 | $14.9B | −19.7% | Open → |
| FY20152015-12-31 | $18.5B | — | Open → |
Shareholders' equity — Shareholders' equity is what remains after subtracting liabilities from assets — the accounting book value of the company, not its market value.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2015–2025 compound annual growth +10.2%
Figures are reported under IFRS, in US dollars.
Shareholders' equity at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=AstraZeneca shareholders' equity |url=https://companiesranked.com/en/company/astrazeneca/shareholders-equity |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). AstraZeneca shareholders' equity. CompaniesRanked. https://companiesranked.com/en/company/astrazeneca/shareholders-equityBibTeX
@misc{companiesranked-en-company-astrazeneca-shareholders-equity-2026,
author = {{CompaniesRanked}},
title = {{AstraZeneca shareholders' equity}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/astrazeneca/shareholders-equity}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0001104659-26-019130 · February 24, 2026
{{cite web |title=AstraZeneca shareholders' equity — 20-F (0001104659-26-019130) |url=https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.